CTRI/2024/01/061874尚未招募Unknown
Proof-of-concept, Open-Label, Two-Arm, Parallel, In-Use Safety and Efficacy Study of test products: ‘RE-Do Beauty Eyebrow Enhancing Serum’ and ‘RE-Do Beauty Eyelash Enhancing Serum’. - NI
V2.0 Cosmetics LLP0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. The subject is aged between 18 and 45 years (both inclusive) at the time of informed consent.
- •2. The subject is a non-pregnant, non-lactating, healthy adult female.
- •3. The subject has a self-reported negative urine pregnancy test.
- •4. The subject is in a good general health as determined from recent medical history.
- •5. The subject does not have any previous history of adverse skin conditions and is not under any medication likely to interfere with the results.
- •6. The subject has willingness and ability to adhere to study directions, participate in the study, and return for all specified visits.
- •7. The subject possesses the ability to comprehend and provide written informed consent for participation in the study.
- •8. The subject agrees not to use any medicated or prescription or other eyebrow and eyelash hair growth products or drugs other than the test product throughout the entire study duration.
- •9. The subject agrees to refrain from undergoing any type of cosmetic or salon enhancement or grooming during the period of the study.
- •10. Few subjects wearing contact lenses shall be included in the study.
- •11. Subjects with sensitive eyes, experiencing lachrymation or mild irritation due to exposure to topical chemicals or strong fumes, will be included in the study, aiming for an equal proportion compared to subjects with non-sensitive eyes.
排除标准
- •1. The subject is currently pregnant or lactating or is planning to become pregnant during the study period.
- •2. The subject is visually impaired or has any underlying condition that may potentially impair their vision.
- •3. The subject has a history of allergies or specific allergic reactions upon using ophthalmic cosmetic products.
- •4. The subject is presenting any ophthalmic condition including but not limited to dry eye, cataract, conjunctivitis.
- •5. The subject experienced stinging or discomfort of anything greater than 0 in the ophthalmic pre-evaluation done with isotonic saline solution.
- •6. The subject is currently enrolled in an active investigational study or has participated in an investigational study within 30 days prior to enrolment.
- •7. The subject suffers from any active clinically significant disease or any condition that according to the discretion of the investigator warrants exclusion from the study.
- •8. The subject is taking or has taken a medication which, in the judgement of the Investigator, makes the subject ineligible or places the subject at undue risk.
研究者
相似试验
已完成
3 期
A Study to Assess the Safety and Efficacy of CoroQuil-Zn 750 in Comparison to the Standard of Care for the Treatment of Mild to Moderate COVID-19.CTRI/2020/12/029735Remedium Therapeutics Private Limited114
已完成
2 期
Testing the efficacy and safety of a blood product COVID-19 Hyper-Immuneglobulin (Human) Solution in Participants with Active COVID-19CTRI/2020/09/027903Intas Pharmaceuticals Limited
已完成
3 期
A clinical trial to test the safety and effectiveness of combination therapy of 2 Ayurvedic products from Jammi Pharmaceuticals for treating women with PCOSCTRI/2021/07/034951Jammi Pharmaceuticals Pvt Ltd
招募中
4 期
A computerized visual training study for visual stimulation in cataract patients following diffractive Intra Ocular lens Implantation.CTRI/2022/08/045110one
进行中(未招募)
不适用
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent PatientsAcute bacterial skin and skin structure infectionsMedDRA version: 18.0Level: HLGTClassification code 10040879Term: Skin investigationsSystem Organ Class: 10022891 - InvestigationsEUCTR2015-002780-42-Outside-EU/EEATrius Therapeutics20
